{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:47:58Z","timestamp":1789480078868,"version":"build-2803163510"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review discusses concepts for diagnosing neuromyelitis optica spectrum disorders (NMOSD), distinguishing NMOSD from other inflammatory diseases of the central nervous system, and highlights recent and forthcoming data on acute and maintenance therapy of NMOSD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The neurologic manifestations of NMOSD are heterogenous, extending beyond classic presentations of optic neuritis and longitudinally extensive transverse myelitis. NMOSD may be comorbid with rheumatologic diseases, such as systemic lupus erythematosus, but is recognized as a distinct entity. Recent studies of acute treatment of NMOSD support early use of plasmapheresis. Relapse prevention is essential, as relapses can be disabling and patients may have only partial recovery. Current practice generally recommends at least 5 years of maintenance treatment. Recent randomized data demonstrates superiority of rituximab over azathioprine. Phase 3 trials have recently been completed or are underway studying novel therapies employing B-cell depletion, complement inhibition, and cell-based mechanisms (among other mechanisms) for maintenance therapy of NMOSD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>NMOSD is a heterogeneous but well-defined clinical entity, distinct from other neurologic and systemic inflammatory diseases, and treatment is poised for expansion.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000603","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T19:44:47Z","timestamp":1553111087000},"page":"250-255","source":"Crossref","is-referenced-by-count":42,"title":["Treatment of neuromyelitis optica spectrum disorders"],"prefix":"10.1097","volume":"31","author":[{"given":"Andrew R.","family":"Romeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult Scler"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11882-016-0619-4","article-title":"Common and rare manifestations of neuromyelitis optica spectrum disorder","volume":"16","author":"Rosales","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch Neurol"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.msard.2015.06.003","article-title":"Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: a meta-analysis","volume":"4","author":"Ruiz-Gaviria","year":"2015","journal-title":"Mult Scler Relat Disord"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J Neurol"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult Scler"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/practneurol-2015-001254","article-title":"Mimics and chameleons of optic neuritis","volume":"16","author":"Weerasinghe","year":"2016","journal-title":"Pract Neurol"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/neu.2016.49","article-title":"Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica","volume":"29","author":"Pereira","year":"2017","journal-title":"Acta Neuropsychiatr"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1002\/art.24937","article-title":"Distinct subtypes of myelitis in systemic lupus erythematosus","volume":"60","author":"Birnbaum","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.semarthrit.2018.02.004","article-title":"Clinical value of autoantibodies for lupus myelitis and its subtypes: a systematic review","volume":"48","author":"Oiwa","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.mayocp.2018.02.006","article-title":"Frequency of aquaporin-4 immunoglobulin G in longitudinally extensive transverse myelitis with antiphospholipid antibodies","volume":"93","author":"Guerra","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/kex328","article-title":"Antibodies to aquaporins are frequent in patients with primary Sjogren's syndrome","volume":"56","author":"Tzartos","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/acr.23107","article-title":"Relationship between neuromyelitis optica spectrum disorder and Sjogren's syndrome: central nervous system extraglandular disease or unrelated, co-occurring autoimmunity?","volume":"69","author":"Birnbaum","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.clinthera.2018.03.007","article-title":"Plasma exchange for neuromyelitis optica spectrum disorders in Chinese patients and factors predictive of short-term outcome","volume":"40","author":"Jiao","year":"2018","journal-title":"Clin Ther"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1212\/NXI.0000000000000005","article-title":"Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica","volume":"1","author":"Levy","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/cen3.12239","article-title":"Bevacizumab is safe in acute relapses of neuromyelitis optica","volume":"6","author":"Mealy","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Mult Scler"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11940-008-0007-z","article-title":"Neuromyelitis optica","volume":"10","author":"Wingerchuk","year":"2008","journal-title":"Curr Treat Options Neurol"},{"key":"R30-20230828","article-title":"Treating neuromyelitis optica with azathioprine: 20-year clinical practice","author":"Bichuetti","year":"2018","journal-title":"Mult Scler"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3389\/fimmu.2018.02066","article-title":"Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in South China","volume":"9","author":"Huang","year":"2018","journal-title":"Front Immunol"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","article-title":"Analysis of the treatment of neuromyelitis optica","volume":"351","author":"Torres","year":"2015","journal-title":"J Neurol Sci"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult Scler"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1177\/1352458517730131","article-title":"Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders","volume":"24","author":"Mealy","year":"2018","journal-title":"Mult Scler"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur J Neurol"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1212\/NXI.0000000000000441","article-title":"Open-label, add-on trial of cetirizine for neuromyelitis optica","volume":"5","author":"Katz Sand","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458517694086","article-title":"Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Yamout","year":"2017","journal-title":"Mult Scler"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00415-015-7925-y","article-title":"Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series","volume":"263","author":"Azzopardi","year":"2016","journal-title":"J Neurol"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1212\/NXI.0000000000000363","article-title":"Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS","volume":"4","author":"Gahlen","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/1352458515620934","article-title":"Placebo-controlled study in neuromyelitis optica-ethical and design considerations","volume":"22","author":"Cree","year":"2016","journal-title":"Mult Scler"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Antiaquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann Neurol"},{"key":"R49-20230828","first-page":"CD010816","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","article-title":"Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder","volume":"74","author":"Zhang","year":"2017","journal-title":"JAMA Neurol"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2014.17986","article-title":"Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis","volume":"313","author":"Burt","year":"2015","journal-title":"JAMA"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamaneurol.2014.3780","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report","volume":"72","author":"Nash","year":"2015","journal-title":"JAMA Neurol"},{"key":"R54-20230828","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"74","author":"Muraro","year":"2017","journal-title":"JAMA Neurol"},{"key":"R55-20230828","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/cns.12559","article-title":"Impact of autologous mesenchymal stem cell infusion on neuromyelitis optica spectrum disorder: a pilot, 2-year observational study","volume":"22","author":"Fu","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","article-title":"Chimeric antigen receptor T cell therapy: 25 years in the making","volume":"30","author":"Gill","year":"2016","journal-title":"Blood Rev"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201905000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:34:20Z","timestamp":1693200860000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201905000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000603","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}